Say hi to MiRXES, a Singapore-based biotech. Founded in 2014, MiRXES uses RNA to make cancer early detection solutions accessible globally!

Oh, and they just secured a whopping $50M Series D!

• This follows up on a $77M Series C round in 2021.

Investor check. The round was led by both existing and new investors, including NHH Venture Fund, Beijing Fupu, EDBI, Mitsui & Co., NHH Venture Fund, and the Agency for Science, Technology and Research.

‍

🎭  Battling the silent killer

One in four people worldwide is diagnosed with cancer. But more than half of these people can be treated — 46% of all patients only discover their cancer in the advanced stages.

• Every month cancer treatment is delayed increases risk of death by 10%, only 14% of cancer is detected early

‍

🧬  RNA to the rescue

The fourth deadliest cancer globally is stomach cancer. 80% of the 1 million diagnosed with it pass away every year, but if detected early, 90% of patients survive.

Stomach cancer is usually diagnosed through gastroscopy, where a flexible tube is inserted and examines inner digestive tracts.

• This method is expensive and invasive.

But GASTROClear’s here to save the day! MiRXES’ flagship product is the world’s first cancer blood test for early detection of stomach cancer.

• It works by measuring levels of microRNA in blood
• This method is non-invasive, less time-consuming, more affordable and highly accurate

You can get tested with GASTROClear today in over 50 clinics and hospitals across Singapore!

• Their expertise in RNA has also enabled them to provide testing solutions to other infectious diseases like COVID.

‍

🧱 Beyond borders

With the new $$$, Mirxes plans to scale adoption of GASTROClear in APAC markets, like SEA, China, and Japan.

• Part of the funds will be used to develop Project CADENCE, a collateral cancer screening test in the form of one blood test to detect early detection of 9 high-morality cancers.

See you soon, IPO? Plus, MiRXES recently applied to list on The Stock Exchange of Hong Kong Limited (HKEX)!

‍

Note: This article's title has been revised to better reflect the substance of the article.